CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Clonazepam

氯硝西泮 杂质对照品Clonazepam Impurities

EP24 个杂质条目24 impurity entries

本页汇总 氯硝西泮 的 24 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 24 impurity reference standards of Clonazepam with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 氯硝西泮(Clonazepam)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesSimultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
    Molecules (Basel, Switzerland) · 2022 · Foudah AI et al.  ·  PMID 35807458  ·  DOI
  2. 杂质研究Impurity studiesStability-indicating RP-HPLC method for the simultaneous determination of escitalopram oxalate and clonazepam
    Journal of chromatographic science · 2013 · Kakde RB et al.  ·  PMID 23135233  ·  DOI
  3. 杂质研究Impurity studiesStability Studies of Clonazepam 2.5 mg/mL Oral Solution and 1 mg/mL Parenteral Solution in Pre-Filled Polypropylene Syringes
    Pharmaceutics · 2025 · Ruiz Ramirez JC et al.  ·  PMID 41155939  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and Validation of an Analytical Method for the Detection and Quantification of Bromazepam, Clonazepam and Diazepam by UPLC-MS/MS in Surface Water
    Bulletin of environmental contamination and toxicology · 2019 · de Araujo FG et al.  ·  PMID 31104081  ·  DOI
  5. 分析方法Analytical MethodsDevelopment and Validation of an LC-MS/MS Method for the Simultaneous Determination of Alprazolam, Bromazepam, Clonazepam, Diazepam and Flunitrazpam in Human Urine and Its Application to Samples from Suspected Drug Abusers
    Molecules (Basel, Switzerland) · 2025 · Kamal H et al.  ·  PMID 40941979  ·  DOI

氯硝西泮 —— 原料药与杂质对照品Clonazepam — drug substance & impurities

共 24 个条目(含原料药本体)24 items incl. the drug substance
Clonazepam Impurity 2 (Clonazepam EP Impurity A) (Clonazepam USP Related Compound B) structure
EPA
氯硝西泮杂质2 (氯硝西泮EP杂质A) (氯硝西泮USP相关化合物B)Clonazepam Impurity 2 (Clonazepam EP Impurity A) (Clonazepam USP Related Compound B)
Clonazepam Impurity 2 (Clonazepam EP Impurity A) (Clonazepam USP Related Compound B)
CAS No.2011-66-7
Chemical FormulaC13H9ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 1 (Clonazepam EP Impurity B) (Clonazepam USP Related Compound A) structure
EPB
氯硝西泮杂质1 (氯硝西泮EP杂质B) (氯硝西泮USP相关化合物A)Clonazepam Impurity 1 (Clonazepam EP Impurity B) (Clonazepam USP Related Compound A)
Clonazepam Impurity 1 (Clonazepam EP Impurity B) (Clonazepam USP Related Compound A)
CAS No.55198-89-5
Chemical FormulaC15H10ClN3O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 3 structure
3
氯硝西泮杂质3Clonazepam Impurity 3
Clonazepam Impurity 3
CAS No.17714-02-2
Chemical FormulaC15H12ClN3O4
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 3 Hydrochloride structure
3
氯硝西泮杂质3 盐酸盐Clonazepam Impurity 3 Hydrochloride
Clonazepam Impurity 3 Hydrochloride
CAS No.94006-04-9
Chemical FormulaC15H12ClN3O4·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 4 structure
4
氯硝西泮杂质4Clonazepam Impurity 4
Clonazepam Impurity 4
CAS No.52130-87-7
Chemical FormulaC15H10BrClN2O4
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 5 structure
5
氯硝西泮杂质5Clonazepam Impurity 5
Clonazepam Impurity 5
CAS No.180854-85-7
Chemical FormulaC15H10Cl2N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 6 structure
6
氯硝西泮杂质6Clonazepam Impurity 6
Clonazepam Impurity 6
CAS No.55501-45-6
Chemical FormulaC13H9ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 10 structure
10
氯硝西泮杂质10Clonazepam Impurity 10
Clonazepam Impurity 10
CAS No.1391053-25-0
Chemical FormulaC28H17Cl2N5O8
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 11 structure
11
氯硝西泮杂质11Clonazepam Impurity 11
Clonazepam Impurity 11
CAS No.2798934-60-6
Chemical FormulaC48H36Cl3N9O12
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 13 structure
13
氯硝西泮杂质13Clonazepam Impurity 13
Clonazepam Impurity 13
CAS No.1647150-35-3
Chemical FormulaC14H8ClN3O2
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 14 structure
14
氯硝西泮杂质14Clonazepam Impurity 14
Clonazepam Impurity 14
CAS No.376613-51-3
Chemical FormulaC15H10BrClN2O4
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 15 structure
15
氯硝西泮杂质15Clonazepam Impurity 15
Clonazepam Impurity 15
CAS No.631861-76-2
Chemical FormulaC15H11ClN2O4
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 16 structure
16
氯硝西泮杂质16Clonazepam Impurity 16
Clonazepam Impurity 16
CAS No.191085-33-3
Chemical FormulaC30H21Cl2N5O8
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 18 structure
18
氯硝西泮杂质18Clonazepam Impurity 18
Clonazepam Impurity 18
CAS No.2245694-97-5
Chemical FormulaC23H14ClN3O6
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 25 structure
25
氯硝西泮杂质25Clonazepam Impurity 25
Clonazepam Impurity 25
CAS No.101928-15-8
Chemical FormulaC17H15ClN4O5
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 26 structure
26
氯硝西泮杂质26Clonazepam Impurity 26
Clonazepam Impurity 26
CAS No.4959-18-6
Chemical FormulaC9H7N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 27 structure
27
氯硝西泮杂质27Clonazepam Impurity 27
Clonazepam Impurity 27
CAS No.191085-32-2
Chemical FormulaC15H10ClIN2O4
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 30 structure
30
氯硝西泮杂质30Clonazepam Impurity 30
Clonazepam Impurity 30
CAS No.16346-60-4
Chemical FormulaC8H6Cl2N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 31 structure
31
氯硝西泮杂质31Clonazepam Impurity 31
Clonazepam Impurity 31
CAS No.4306-32-5
Chemical FormulaC8H5Cl3N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 35 structure
35
氯硝西泮杂质35Clonazepam Impurity 35
Clonazepam Impurity 35
CAS No.24863-73-8
Chemical FormulaC20H12Cl2N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 36 structure
36
氯硝西泮杂质36Clonazepam Impurity 36
Clonazepam Impurity 36
CAS No.4980-76-1
Chemical FormulaC13H9ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 38 structure
38
氯硝西泮杂质38Clonazepam Impurity 38
Clonazepam Impurity 38
CAS No.2250255-28-6
Chemical FormulaC13H9ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 42 structure
42
氯硝西泮杂质42Clonazepam Impurity 42
Clonazepam Impurity 42
CAS No.66938-60-1
Chemical FormulaC13H9ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clonazepam Impurity 43 structure
43
氯硝西泮杂质43Clonazepam Impurity 43
Clonazepam Impurity 43
CAS No.613656-93-2
Chemical FormulaC13H9ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

氯硝西泮 —— 研究文献与合成路线Clonazepam — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 氯硝西泮 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Clonazepam. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Analysis of clonazepam in a tablet dosage form using smallbore HPLC
    Spell JC, Stewart JT · Journal of pharmaceutical and biomedical analysis · 1998 · 被引 14cited 14
  2. Validated spectrofluorimetric method for the determination of clonazepam in pharmaceutical preparations
    Ibrahim F, El-Enany N, Shalan S, et al. · Luminescence : the journal of biological and chemical luminescence · 2016 · 被引 6cited 6
  3. Simultaneous Estimation of Escitalopram and Clonazepam in Tablet Dosage Forms Using HPLC-DAD Method and Optimization of Chromatographic Conditions by Box-Behnken Design
    Foudah AI, Alshehri S, Shakeel F, et al. · Molecules (Basel, Switzerland) · 2022 · 被引 3cited 3
  4. Spectrophotometric and reversed-phase high-performance liquid chromatographic methods for simultaneous determination of escitalopram oxalate and clonazepam in combined tablet dosage form
    Gandhi SV, Dhavale ND, Jadhav VY, et al. · Journal of AOAC International · 2008 · 被引 6cited 6
  5. A Synchronous Fluorescence Spectrofluorometric Method for the Simultaneous Determination of Clonazepam and Paroxetine Hydrochloride in Combined Pharmaceutical Dose Form
    Patel JU, Chhalotiya UK, Shah PA · Turkish journal of pharmaceutical sciences · 2017 · 被引 1cited 1

合成路线文献Synthetic-route papers

  1. Synthesis of superparamagnetic Fe3O4-graphene oxide-based material for the photodegradation of clonazepam
    da Silva MP, de Souza ACA, Ferreira ÁRD, et al. · Scientific reports · 2024
  2. Euterpe oleracea-based biochar for clonazepam adsorption: synthesis, characterization, adsorption properties, and toxicity assays
    Santos RKS, Schnorr C, Silva LFO, et al. · Environmental science and pollution research international · 2023
  3. Computer-assisted design and synthesis of a highly selective smart adsorbent for extraction of clonazepam from human serum
    Aqababa H, Tabandeh M, Tabatabaei M, et al. · Materials science & engineering. C, Materials for biological applications · 2013

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

氯硝西泮 杂质谱研究要点Clonazepam — impurity profiling notes

下面这些是拿到 氯硝西泮 的 24 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 24 impurity entries for Clonazepam, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances